-
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:18-cv-00193
- N.D.W. Va.
- Judge: John Preston Bailey +1
- Filed: 10/12/2018
- Closed: 03/08/2023
- Latest Docket Entry: 03/28/2024
- PACER
- Docket updated daily
2
Plaintiffs
5
Defendants
2
Accused
Products
4
Patents-in-Suit
1,609
Days in
Litigation
-
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al DC CAFC
- 1:18-cv-00193
- N.D.W. Va.
- Judge: John Preston Bailey +1
- Filed: 10/12/2018
- Closed: 03/08/2023
- Latest Docket Entry: 03/28/2024
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
9 |
The method of claim 4, wherein the concentration of budesonide is 2 mg/ml.
|
Enforceable and Valid
Entry 438 |
10 |
The method of claim 4, wherein the concentration of budesonide is 4 mg/ml.
|
Enforceable and Valid
Entry 438 |
13 |
A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 2
view more
|
Enforceable and Valid
Entry 438 |
14 |
A pharmaceutical composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the formoterol fumarate dihydrate is present at a concentration of 0.09 mg/ml, the budesonide is present at a concentration of 4
view more
|
Enforceable and Valid
Entry 438 |
Claim # | Claim Text | Outcome |
---|---|---|
12 |
The inhaler of claim 10, wherein an actuation of the inhaler delivers 80 μg budesonide.
|
Enforceable and Valid
Entry 438 |
13 |
The inhaler of claim 10, wherein an actuation of the inhaler delivers 160 μg budesonide.
|
Enforceable and Valid
Entry 438 |
18 |
The method of claim 16, wherein an actuation of the inhaler delivers 80 μg budesonide.
|
Enforceable and Valid
Entry 438 |
19 |
The method of claim 16, wherein an actuation of the inhaler delivers 160 μg budesonide.
|
Enforceable and Valid
Entry 438 |
Claim # | Claim Text | Outcome |
---|---|---|
10 |
The pharmaceutical suspension composition of claim 9, wherein the PEG-1000 is present at a concentration of 0.3% w/w.
|
Enforceable and Valid
Entry 438 |
19 |
A method of treating a respiratory disorder, the method comprising administering the pharmaceutical suspension composition of claim 10 to a patient identified as in need of treatment with the composition.
|
Enforceable and Valid
Entry 438 |
Claim # | Claim Text | Outcome |
---|---|---|
2 |
The composition according toclaim 1 wherein the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w.
|
Invalid
Entry 607 |
3 |
The pharmaceutical composition according toclaim 1 in which the PVP is PVP K25.
|
Invalid
Entry 607 |
-
Infringement
Kindeva Drug Delivery L.P.
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 7,759,328 B2 |
9, 10, 13, 14
|
Infringement
Entry 438
|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 8,143,239 B2 |
12, 13, 18, 19
|
Infringement
Entry 438
|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 8,575,137 B2 |
10, 19
|
Infringement
Entry 438
|
Mylan Pharmaceuticals Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 7,759,328 B2 |
9, 10, 13, 14
|
Infringement
Entry 438
|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 8,143,239 B2 |
12, 13, 18, 19
|
Infringement
Entry 438
|
Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol 160 mcg/4.5 mcgBudesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol, 80 mcg/4.5 mcg | US 8,575,137 B2 |
10, 19
|
Infringement
Entry 438
|